Stockscreener 앱 받기
0.4123
3.05%
0.0122
시간 외 거래:
.41
-0.0023
-0.56%
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Energy Focus, Inc. (EFOI) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
Ensysce Biosciences, Inc. (ENSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ensysce Biosciences, Inc. (ENSC) Latest Stock News & Headlines - Yahoo! Finance Canada
Ensysce submits Phase 2a protocol for CRPS treatment CY200 - Investing.com
Ensysce submits Phase 2a protocol for CRPS treatment CY200 By Investing.com - Investing.com UK
Ensysce Biosciences Phase 2 Protocol for CY200A Neuroplastigen for the Treatment of CRPSSubmitted to the UK MHRA - Corsicana Daily Sun
A study plan for a pain condition with no treatment that cures it reaches UK regulators. - Stock Titan
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce hosts symposium at PainWeek, attends FDA hearing By Investing.com - Investing.com Canada
Ensysce hosts symposium at PainWeek, attends FDA hearing - Investing.com
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation - Corsicana Daily Sun
More than 320 pain professionals attended Ensysce’s symposium on complex pain. - Stock Titan
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - kalkine.com.au
A doctor from Ensysce is among a limited group chosen to speak at an FDA psychedelic hearing - Stock Titan
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Corsicana Daily Sun
ORCL: Oracle Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
ENSC Q2 2026 Earnings: 60.78% EPS Beat Buys Optionality as Pre-Revenue Pipeline AdvancesEarnings Yield Analysis - dars.gov.et
An FDA hearing on psychedelic drugs is set for Sept. 14. Ensysce will take part. - Stock Titan
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Yahoo Finance
Ensysce completes PF614-MPAR-102 clinical enrollment - grafa.com
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Australia
Ensysce completes enrollment in opioid overdose study - Investing.com India
An opioid study from Ensysce is fully enrolled to test overdose protection - stocktitan.net
Ensysce Faces Nasdaq Delisting Risk After Cy Biopharma Deal Triggers Change of Control - minichart.com.sg
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period - The Globe and Mail
Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period - TradingView
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; After Earnings: The Stock Ends Down 3.87% for the Current SessionEarnings Yield Spread - vinanet.vn
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
3.06%
2.55%
자본화:
|
볼륨(24시간):